Literature DB >> 17056581

Poly(ADP-ribose) polymerase-1 inhibition prevents eosinophil recruitment by modulating Th2 cytokines in a murine model of allergic airway inflammation: a potential specific effect on IL-5.

Mustapha Oumouna1, Oumouna Mustapha, Rahul Datta, Karine Oumouna-Benachour, Yasuhiro Suzuki, Chetan Hans, Kametra Matthews, Kenneth Fallon, Hamid Boulares.   

Abstract

We recently used a murine model of allergic airway inflammation to show that poly(ADP-ribose) polymerase-1 (PARP-1) plays an important role in the pathogenesis of asthma-related lung inflammation. In this study, we show that PARP-1 inhibition, by a novel inhibitor (TIQ-A) or by gene deletion, prevented eosinophilic infiltration into the airways of OVA-challenged mice. Such impairment of eosinophil recruitment appeared to take place after IgE production. OVA challenge of wild-type mice resulted in a significant increase in IL-4, IL-5, IL-10, IL-13, and GM-CSF secretions. Although IL-4 production was moderately affected in OVA-challenged PARP-1(-/-) mice, the production of IL-5, IL-10, IL-13, and GM-CSF was completely inhibited in ex vivo OVA-challenged lung cells derived from these animals. A single TIQ-A injection before OVA challenge in wild-type mice mimicked the latter effects. The marked effect PARP-1 inhibition exerted on mucus production corroborated the effects observed on the Th2 response. Although PARP-1 inhibition by gene knockout increased the production of the Th1 cytokines IL-2 and IL-12, the inhibition by TIQ-A exerted no effect on these two cytokines. The failure of lung cells derived from OVA-challenged PARP-1(-/-) mice to synthesize GM-CSF, a key cytokine in eosinophil recruitment, was reestablished by replenishment of IL-5. Furthermore, intranasal administration of IL-5 restored the impairment of eosinophil recruitment and mucus production in OVA-challenged PARP-1(-/-) mice. The replenishment of either IL-4 or IgE, however, did not result in such phenotype reversals. Altogether, these results suggest that PARP-1 plays a critical role in eosinophil recruitment by specifically regulating the cascade leading to IL-5 production.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17056581     DOI: 10.4049/jimmunol.177.9.6489

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model.

Authors:  R Datta; A S Naura; M Zerfaoui; Y Errami; M Oumouna; H Kim; J Ju; V P Ronchi; A L Haas; A H Boulares
Journal:  Allergy       Date:  2011-01-28       Impact factor: 13.146

2.  The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.

Authors:  Akbar Ahmad; Gabor Olah; David N Herndon; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-05       Impact factor: 8.739

3.  Nuclear translocation of p65 NF-kappaB is sufficient for VCAM-1, but not ICAM-1, expression in TNF-stimulated smooth muscle cells: Differential requirement for PARP-1 expression and interaction.

Authors:  Mourad Zerfaoui; Yasuhiro Suzuki; Amarjit S Naura; Chetan P Hans; Charles Nichols; A Hamid Boulares
Journal:  Cell Signal       Date:  2007-10-12       Impact factor: 4.315

Review 4.  Metabolic checkpoints in activated T cells.

Authors:  Ruoning Wang; Douglas R Green
Journal:  Nat Immunol       Date:  2012-09-18       Impact factor: 25.606

5.  Negative transcriptional regulation of inflammatory genes by group B3 vitamin nicotinamide.

Authors:  Xiao-Ming Zhang; Yu-Ping Jing; Meng-Ying Jia; Li Zhang
Journal:  Mol Biol Rep       Date:  2012-10-07       Impact factor: 2.316

6.  Poly (ADP-ribose) polymerase 14 and its enzyme activity regulates T(H)2 differentiation and allergic airway disease.

Authors:  Purvi Mehrotra; Andrew Hollenbeck; Jonathan P Riley; Fang Li; Ravi J Patel; Nahid Akhtar; Shreevrat Goenka
Journal:  J Allergy Clin Immunol       Date:  2012-07-25       Impact factor: 10.793

Review 7.  Beyond DNA repair, the immunological role of PARP-1 and its siblings.

Authors:  Maria Manuela Rosado; Elisabetta Bennici; Flavia Novelli; Claudio Pioli
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

8.  PARP inhibition treatment in a nonconventional experimental mouse model of chronic asthma.

Authors:  Raffaela Zaffini; Rosanna Di Paola; Salvatore Cuzzocrea; Marta Menegazzi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-07       Impact factor: 3.000

9.  High-fat diet induces lung remodeling in ApoE-deficient mice: an association with an increase in circulatory and lung inflammatory factors.

Authors:  Amarjit S Naura; Chetan P Hans; Mourad Zerfaoui; Youssef Errami; Jihang Ju; Hogyoung Kim; Khalid Matrougui; Jong G Kim; A Hamid Boulares
Journal:  Lab Invest       Date:  2009-09-14       Impact factor: 5.662

10.  Protective effects of PARP-1 knockout on dyslipidemia-induced autonomic and vascular dysfunction in ApoE mice: effects on eNOS and oxidative stress.

Authors:  Chetan P Hans; Yumei Feng; Amarjit S Naura; Mourad Zerfaoui; Bashir M Rezk; Huijing Xia; Alan D Kaye; Khalid Matrougui; Eric Lazartigues; A Hamid Boulares
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.